NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Vobramitamab duocarmazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
Vobramitamab duocarmazine
DrugBank Accession Number
DB18871
Background

Vobramitamab duocarmazine is under investigation in clinical trial NCT05551117 (A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors).

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Anti-b7h3 antibody-drug conjugate mgc018
External IDs
  • MGC-018
  • MGC018
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
2ZK3D69DQJ
CAS number
2490556-51-7

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
2Active Not RecruitingTreatmentAnal Cancer / Anal Neoplasms / Androgen Resistant Prostatic Cancer / Androgen-Independent Prostatic Cancer / Androgen-Insensitive Prostatic Cancer / Carcinoma, Non-Small Cell / Castration Resistant Prostate Cancer / Hormone Refractory Prostatic Cancer / Laryngeal Squamous Cell Carcinoma / Malignant Melanoma / Melanoma / Non-Small Cell Lung Cancer (NSCLC) / Small Cell Carcinoma / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Squamous Cell Carcinoma of the Oral Cavity1somestatusstop reasonjust information to hide
2RecruitingTreatmentExtensive-stage Small Cell Lung Cancer (SCLC)1somestatusstop reasonjust information to hide
1RecruitingTreatmentAdvanced Solid Tumors / Castration Resistant Prostate Cancer / Epithelial Ovarian Cancer / Liver Cancer / Malignant Melanoma / Pancreatic Ductal Adenocarcinoma (PDAC) / Renal Cell Carcinoma (RCC)1somestatusstop reasonjust information to hide
1, 2TerminatedTreatmentAdvanced Solid Tumor, Adult / Melanoma / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Non-Small Cell Lung Cancer (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Triple-Negative Breast Cancer1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at June 26, 2024 20:40 / Updated at June 29, 2024 07:29